Vor Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

Core Insights - Vor Bio has initiated a global Phase 3 clinical trial for telitacicept in primary Sjögren's disease, with the first patient dosed shortly after the trial's commencement [1][2] - The company has successfully completed a $75 million private placement to enhance its balance sheet and support the global clinical development of telitacicept [1][4] - As of December 31, 2025, Vor Bio's pro-forma cash and investment balance is projected to be $530.2 million, providing operational runway into early 2029 [1][4] Clinical Development - Telitacicept is being developed as a dual BAFF/APRIL inhibitor for generalized myasthenia gravis (gMG) and primary Sjögren's disease (SjD) [3][6] - Enrollment is ongoing in a randomized, double-blind, placebo-controlled Phase 3 trial for gMG, with topline data expected in the first half of 2027 [4] - The promising Phase 3 results from telitacicept in China across multiple indications, including gMG and SjD, are seen as a strong foundation for further development [2] Financial Performance - R&D expenses for Q4 2025 were $19.2 million, down from $25.3 million in Q4 2024, primarily due to lower stock-based compensation and personnel costs [4][5] - For the year ended December 31, 2025, R&D expenses totaled $321.5 million, a significant increase from $93.3 million in 2024, driven by costs associated with the telitacicept license and increased spending on clinical trials [5] - General and administrative expenses for Q4 2025 were $16.8 million, up from $6.0 million in Q4 2024, largely due to increased stock-based compensation and professional service costs [12] Corporate Updates - Vor Bio appointed Andrew Levin, M.D., Ph.D., and Wouter Joustra to its Board of Directors to strengthen its leadership [4] - The company is advancing its global development programs for telitacicept to support potential regulatory approvals in the U.S., Europe, and Japan [8][9]